Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
This product is intended for laboratory research use only and is not approved for human or veterinary use
Products are not for human or veterinary use, not for use in diagnostic procedures, and have not been evaluated by the U.S
Tirzepatide was first approved for diabetes treatment in 2022 under the brand name Mounjaro after initial studies demonstrated its effectiveness in lowering blood sugar (5)
Writing original draft: Hani Haytham Mawardi, Ali Anwar Aboalola, Thamer Abdulmohsin Al-Ghalib, Rawah Talal Eshky, Adham Abdulmajeed Niyazi, Mohammed Haytham Mawardi
Because it is not an aqueous solution, the bacteriostatic-water storage windows used for injectable peptides do not apply
US$ 20.33
US$ 27.28
US$ 27.19
US$ 25.15
US$ 28.06
